Archeon Medical expands into the US market, strengthening global presence.

NEW-YORK CITY – 12.17.2024. Archeon Medical is thrilled to announce the establishment of a subsidiary in the United States. This strategic move reinforces its commitment to the North American market. This will enable enhanced support for a growing customer base and accelerate the adoption of its life-saving technologies.

Building on the remarkable success of its groundbreaking ventilation feedback device, EOlife, in the United States—which accounts for 60% of its total revenue in 2024—Archeon Medical establishes a local presence in this key market. Furthermore, EOlife has revolutionized the field of manual ventilation by offering a more efficient and personalized approach to patient care. In addition, by providing accurate, real-time measurements of delivered tidal volume, EOlife has transformed cardiopulmonary resuscitation (CPR), setting a new standard for airway management.

“The United States is a pivotal market for Archeon Medical. We are poised to accelerate the adoption of our innovative solutions and further improve patient care. EOlife has already made a significant impact on patient care in the US. With our expanded presence through, we aim to build on this success and continue to revolutionize the field of manual ventilation.”  

Valentine Oqda, Head of US operations at Archeon Medical.

TRUSTED BY LEADING HEALTHCARE INSTITUTIONS

A COMMITMENT TO EXCELLENCE

About Archeon Medical
Founded in 2018, by Alban De Luca and Pierre-Edouard Saillard, Archeon Medical is a pioneer in emergency medical technology. Archeon Medical developed EOlife, the ventilation feedback device has transformed the way healthcare providers approach manual ventilation. By providing real-time feedback and ensuring adherence to guidelines, EOlife empowers medical teams to deliver life-saving care to patients in critical condition. With a global footprint and a commitment to innovation, Archeon is dedicated to improving patient outcomes worldwide.